Advertisement

Early Stage Discovery and Validation of Pharmacological Chaperones for the Correction of Protein Misfolding Diseases

  • Oscar Aubi
  • Per M. Knappskog
  • Aurora MartinezEmail author
Protocol
Part of the Methods in Molecular Biology book series (MIMB, volume 1873)

Abstract

Pharmacological chaperones are small molecular weight molecules that bind specifically to protein targets and stabilize unstable and misfolded conformations. In particular, there is an increasing interest in the application of this type of compounds for the correction of genetic conformational disorders, which are caused by mutations leading to protein instability. The discovery of compounds with pharmacological chaperone ability is customarily initiated by a high-throughput screening of chemical libraries searching for stabilizing binders. However, there is no established consensus for the subsequent steps. Therefore, here, we introduce an example of a successful protocol directed to the discovery of pharmacological chaperones with potential for the therapeutic correction of phenylketonuria, a defect caused by mutations in the enzyme phenylalanine hydroxylase.

Keywords

Drug discovery and development Orthogonal binding assays Functional assays 

Notes

Acknowledgments

This work was supported by The Research Council of Norway (RCN; Program Forny2020 248889/O30 and FRIMEDBIO 214012), the infrastructure project Nor-Openscreen (RCN), and The K.G. Jebsen Foundation. We thank Guri E. Matre and Ming Ying for expert technical assistance.

References

  1. 1.
    Chen B, Retzlaff M, Roos T, Frydman J (2011) Cellular strategies of protein quality control. Cold Spring Harb Perspect Biol 3(8):a004374CrossRefGoogle Scholar
  2. 2.
    Sontag EM, Samant RS, Frydman J (2017) Mechanisms and functions of spatial protein quality control. Annu Rev Biochem 86:97–122CrossRefGoogle Scholar
  3. 3.
    Kevei E, Pokrzywa W, Hoppe T (2017) Repair or destruction-an intimate liaison between ubiquitin ligases and molecular chaperones in proteostasis. FEBS Lett 591(17):2616–2635CrossRefGoogle Scholar
  4. 4.
    Muntau AC, Leandro J, Staudigl M, Mayer F, Gersting SW (2014) Innovative strategies to treat protein misfolding in inborn errors of metabolism: pharmacological chaperones and proteostasis regulators. J Inherit Metab Dis 37(4):505–523CrossRefGoogle Scholar
  5. 5.
    Labbadia J, Morimoto RI (2015) The biology of proteostasis in aging and disease. Annu Rev Biochem 84:435–464CrossRefGoogle Scholar
  6. 6.
    Hartl FU (2017) Protein misfolding diseases. Annu Rev Biochem 86:21–26CrossRefGoogle Scholar
  7. 7.
    Blau N, van Spronsen FJ, Levy HL (2010) Phenylketonuria. Lancet 376(9750):1417–1427CrossRefGoogle Scholar
  8. 8.
    Flydal MI, Martinez A (2013) Phenylalanine hydroxylase: function, structure, and regulation. IUBMB Life 65(4):341–349CrossRefGoogle Scholar
  9. 9.
    Wettstein S, Underhaug J, Perez B, Marsden BD, Yue WW, Martinez A, Blau N (2015) Linking genotypes database with locus-specific database and genotype-phenotype correlation in phenylketonuria. Eur J Hum Genet 23(3):302–309CrossRefGoogle Scholar
  10. 10.
    Underhaug J, Aubi O, Martinez A (2012) Phenylalanine hydroxylase misfolding and pharmacological chaperones. Curr Top Med Chem 12(22):2534–2545CrossRefGoogle Scholar
  11. 11.
    Convertino M, Das J, Dokholyan NV (2016) Pharmacological chaperones: design and development of new therapeutic strategies for the treatment of conformational diseases. ACS Chem Biol 11(6):1471–1489CrossRefGoogle Scholar
  12. 12.
    Pey AL, Ying M, Cremades N, Velazquez-Campoy A, Scherer T, Thony B, Sancho J, Martinez A (2008) Identification of pharmacological chaperones as potential therapeutic agents to treat phenylketonuria. J Clin Invest 118(8):2858–2867CrossRefGoogle Scholar
  13. 13.
    Hole M, Jorge-Finnigan A, Underhaug J, Teigen K, Martinez A (2016) Pharmacological chaperones that protect Tetrahydrobiopterin dependent aromatic amino acid hydroxylases through different mechanisms. Curr Drug Targets 17(13):1515–1526CrossRefGoogle Scholar
  14. 14.
    Lee JA, Carragher NO, Berg EL (2017) Empirical drug discovery: a view from the proteome. Drug Discov Today Technol 23:1–5CrossRefGoogle Scholar
  15. 15.
    Wang J, Zhang X, Fang Y, Liang X (2016) Label-free cell phenotypic assays for assessing drug polypharmacology. Curr Pharm Des 22(21):3190–3200CrossRefGoogle Scholar
  16. 16.
    Schenone M, Dancik V, Wagner BK, Clemons PA (2013) Target identification and mechanism of action in chemical biology and drug discovery. Nat Chem Biol 9(4):232–240CrossRefGoogle Scholar
  17. 17.
    Flatmark T, Stokka AJ, Berge SV (2001) Use of surface plasmon resonance for real-time measurements of the global conformational transition in human phenylalanine hydroxylase in response to substrate binding and catalytic activation. Anal Biochem 294(2):95–101CrossRefGoogle Scholar
  18. 18.
    Martínez A, Knappskog PM, Olafsdottir S, Døskeland AP, Eiken HG, Svebak RM, Bozzini M, Apold J, Flatmark T (1995) Expression of recombinant human phenylalanine hydroxylase as fusion protein in Escherichia coli circumvents proteolytic degradation by host cell proteases. Isolation and characterization of the wild-type enzyme. Biochem J 306:589–597CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  • Oscar Aubi
    • 1
  • Per M. Knappskog
    • 2
    • 3
  • Aurora Martinez
    • 1
    • 3
    Email author
  1. 1.Department of BiomedicineUniversity of BergenBergenNorway
  2. 2.Center for Medical Genetics and Molecular MedicineHaukeland University HospitalBergenNorway
  3. 3.K. G. Jebsen Centre for Neuropsychiatric DisordersBergenNorway

Personalised recommendations